# RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

> **NCT05733611** · PHASE2 · TERMINATED · sponsor: **Replimune, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Refractory Metastatic Colorectal Cancer
- pMMR
- MSS

## Interventions

- **BIOLOGICAL:** RP2
- **BIOLOGICAL:** RP3
- **BIOLOGICAL:** atezolizumab
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT05733611
- **Lead sponsor:** Replimune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-29
- **Primary completion:** 2025-08-18
- **Final completion:** 2025-08-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business reasons.
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733611, "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05733611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*